SAN DIEGO — The U.S. Food and Drug Administration (FDA) is undergoing a significant cultural and operational transformation amid growing U.S.–China competition in biotechnology. This shift is prompting a reevaluation of regulatory frameworks, particularly concerning rare diseases, and emphasizes the need for integrating patient perspectives into the drug development continuum.
These themes were central to a town hall discussion at the Biotechnology Innovation Organization (BIO) meeting in San Diego, featuring key FDA leaders. Moderated by BIO president John Crowley, the panel included acting directors from the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), who outlined the agency’s priorities and workforce stabilization efforts following recent staffing reductions.
Panelists acknowledged the operational disruptions caused by these staffing changes but focused on the importance of rebuilding the agency’s workforce to support upcoming initiatives. Acting CDER director Michael Davis highlighted workforce fortification as a top priority, while also addressing recruitment strategies to fill over 2,200 authorized positions. The FDA’s commitment to minimizing attrition and enhancing staff morale is seen as crucial for executing its mission effectively.
Additionally, the FDA is pushing for modernization in clinical development, with recent actions aimed at streamlining submission processes under Operation TrailBlazer. This initiative reflects a shift towards adaptive design in drug development, ensuring that patient perspectives are integral to the process. The agency’s response to increasing competition from China, particularly in clinical trial infrastructure, underscores its role in maintaining U.S. leadership in biotech innovation, which is now tied to national security considerations.
Start your 7-day trial and see what the database can do →
